| HORIZON | TRADES | WIN RATE | INSIDER RETURN | SPY RETURN | MEAN EXCESS | MEDIAN EXCESS | T-STAT |
|---|---|---|---|---|---|---|---|
| 7d | 1 | +0.00% | +17.76% | +0.28% | +17.47% | +17.47% | — |
| 14d | 1 | +0.00% | +10.28% | -2.06% | +12.34% | +12.34% | — |
| 30d | 1 | +100.00% | -0.94% | -2.05% | +1.12% | +1.12% | — |
| 60d | 1 | +0.00% | +166.35% | -2.81% | +169.16% | +169.16% | — |
| 90d | 1 | +0.00% | +214.95% | -4.75% | +219.71% | +219.71% | — |
| 180d | 1(1 pending) | — | — | — | — | — | — |
| 1y | 1(1 pending) | — | — | — | — | — | — |
| 2y | 1(1 pending) | — | — | — | — | — | — |
| COMPANY | TYPE | SHARES | PRICE | VALUE | HELD AFTER | TRADE DATE | FILED | DETAILS |
|---|---|---|---|---|---|---|---|---|
| ANTX AN2 THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 82,300 | — | — | 82,300 | Mar 19, 2026 | Mar 23, 2026 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | SALE Chief Financial Officer | 73,665 | — | — | 0 | Mar 19, 2026 | Mar 23, 2026 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | SALE Chief Financial Officer | 82,300 | — | — | 0 | Mar 19, 2026 | Mar 23, 2026 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 73,665 | — | — | 73,665 | Mar 19, 2026 | Mar 23, 2026 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 66,000 | — | — | 66,000 | Mar 19, 2026 | Mar 23, 2026 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | SALE Chief Financial Officer | 66,000 | — | — | 0 | Mar 19, 2026 | Mar 23, 2026 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 38,000 | — | — | 118,363 | Feb 20, 2026 | Feb 23, 2026 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | SALEGRANT Stock grant | 77,000 | — | — | 77,000 | Feb 20, 2026 | Feb 23, 2026 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | SALE Chief Financial Officer | 5,512 | $1.01 | $5.6K | 75,363 | Jan 6, 2026 | Jan 7, 2026 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | SALE Chief Financial Officer | 3,295 | $1.00 | $3.3K | 80,875 | Jan 5, 2026 | Jan 7, 2026 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | SALEGRANT Stock grant | 93,000 | — | — | 93,000 | Feb 26, 2025 | Feb 28, 2025 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 46,500 | — | — | 79,170 | Feb 26, 2025 | Feb 28, 2025 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | SALE Chief Financial Officer | 2,957 | $1.34 | $4.0K | 32,670 | Jan 3, 2025 | Jan 7, 2025 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 27,500 | — | — | 30,627 | Mar 15, 2024 | Mar 18, 2024 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 55,000 | — | — | 55,000 | Mar 15, 2024 | Mar 18, 2024 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 27,500 | — | — | 30,627 | Mar 15, 2024 | Mar 29, 2024 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 82,300 | — | — | 82,300 | Feb 15, 2023 | Feb 17, 2023 ↗ | View → |
| ANTX AN2 THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 66,000 | — | — | 66,000 | May 12, 2022 | May 16, 2022 ↗ | View → |